Navigation Links
Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Melanoma
Date:6/2/2011

EXTON, Pa., June 2, 2011 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center, phase II study of MORAb-004 for the treatment of metastatic melanoma. The study will evaluate MORAb-004, a potentially first-in-class monoclonal antibody that specifically binds to endosialin/tumor endothelial marker-1 (TEM-1), as a single agent therapy comparing its safety and therapeutic activity at two dosages.

The trial is designed as an open-label study to assess the efficacy of single agent MORAb-004 at one of two doses as determined by progression-free survival in patients with metastatic melanoma. Secondary objectives include assessment of an overall survival benefit, identification of an optimal dose, identification of biomarkers to predict efficacy, and safety of single agent MORAb-004. The patient population includes individuals with metastatic melanoma who have received at least one previous drug regimen.  It is estimated that nearly all metastatic melanoma tumors are endosialin/TEM-1 positive.(1)

Morphotek expects to enroll up to 80 patients in this study, which is being conducted at clinical centers in the United States, Europe and Australia.  As part of the trial, patient tumors will be tested for endosialin/TEM-1 and/or proteins within its pathway to determine if the pattern of expression relates to or determines clinical effect.

"We are excited to have initiated this phase II study of MORAb-004 in melanoma," stated Christina Coughlin, M.D., Ph.D. Senior Director of Clinical Development at Morphotek. "New agents are needed for the treatment of metastatic melanoma which remains an area of significant unmet medical need in the field of oncology. We are pleased to have the opportunity to collaborate with several of the world's experts in this disease setting."

MORAb-004 is a humanized monoclonal antibody specific for endosialin/TEM-1 protein.  The target is found to be expressed on the cell surface of cells called pericytes that are part of the tumor blood vessel architecture, as well as on fibroblast cells that are part of the tumor stroma.  Morphotek obtained exclusive worldwide rights to develop and commercialize this antibody from the Ludwig Institute for Cancer Research (LICR).

Further information on the clinical study can be found at www.clinicaltrials.gov, study number NCT01335009.

About MorphotekMorphotek®, Inc., a subsidiary of Eisai Inc., is a biopharmaceutical company specializing in the development of protein and antibody products through the use of a novel and proprietary gene evolution technology.  The technology has been successfully applied to a broad variety of cell lines and organisms to yield genetically diverse offspring that are suitable for pharmaceutical product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications.  The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease.  For more information, please visit www.morphotek.com.  

About Eisai Inc.Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales).  The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business.  Eisai's areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care.  The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.  

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina.  The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs.  For more information about Eisai, please visit www.eisai.com/us.

(1) Data on file, Morphotek, Inc.Contacts:  

Media Inquiries

Investor InquiriesTerry Cushmore

Rod DauschMorphotek, Inc.

Morphotek, Inc.610-423-6197

610-423-6111tcushmore@morphotek.com

Dausch@morphotek.comMedia Inquiries

Investor InquiriesLynn Kenney

Alex ScottEisai Inc.

Eisai Inc.201-746-2294

201-746-2177lynn_kenney@eisai.com

alex_scott@eisai.com
'/>"/>

SOURCE Morphotek, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Morphotek®, Inc. Receives Beacon Award From CancerCare
2. Morphotek®, Inc. Announces an Agreement with Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Folate Receptor Alpha in Malignant Tissues
3. Adeona Announces Positive Alzheimers Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy
4. Regal One Announces Dividend of Rampart Detection Systems Common Stock
5. PharmaNet Announces Tender Offer and Consent Solicitation
6. Biomatrica Announces the Appointment of Dr. James A. Robb as a Member of the Scientific Advisory Board
7. Sequenom Announces Participation at Jefferies 2011 Global Healthcare Conference
8. WaferGen Announces $30 Million Financing
9. Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
10. Vermillion Announces Notice of Allowance for Alzheimer Patent
11. VIVUS Announces Positive Phase 3 Results of Avanafil in Radical Prostatectomy Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published ... how a patient who developed lymphedema after being treated for breast cancer benefitted from ... the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... , June 23, 2016 On ... session at 4,833.32, down 0.22%; the Dow Jones Industrial Average ... 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez ... Inc. (NASDAQ: BIND ). Learn more about these ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... quality, regulatory and technical consulting, provides a free webinar on Performing ... July 13, 2016 at 12pm CT at no charge. , Incomplete investigations are ...
Breaking Biology Technology:
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
Breaking Biology News(10 mins):